Has the U.K. Pharma Industry valuation changed over the past few years?

Investors are pessimistic on the British Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically. The industry is trading at a PE ratio of 19.3x which is lower than its 3-year average PE of 25.0x. The industry is trading close to its 3-year average PS ratio of 3.4x.

Which industries have driven the changes within the U.K. Healthcare industry?

There are no additional sub-industries under this industry.

U.K. (FTSE) Pharma Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Wed, 15 Jul 2026	UK£305.5b	UK£92.1b	UK£15.8b	19x	19.3x	3.3x
Fri, 12 Jun 2026	UK£324.1b	UK£92.0b	UK£15.8b	17.8x	20.5x	3.5x
Sun, 10 May 2026	UK£315.7b	UK£91.3b	UK£15.7b	17.6x	20.1x	3.5x
Tue, 07 Apr 2026	UK£362.2b	UK£91.4b	UK£15.7b	20x	23x	4x
Thu, 05 Mar 2026	UK£358.1b	UK£90.8b	UK£15.7b	21.6x	22.9x	3.9x
Sat, 31 Jan 2026	UK£325.6b	UK£88.5b	UK£14.5b	23.7x	22.5x	3.7x
Mon, 29 Dec 2025	UK£323.1b	UK£89.2b	UK£14.6b	21.8x	22.2x	3.6x
Wed, 26 Nov 2025	UK£329.9b	UK£90.4b	UK£14.8b	21.9x	22.3x	3.6x
Fri, 24 Oct 2025	UK£297.5b	UK£88.1b	UK£11.8b	20.6x	25.3x	3.4x
Sun, 21 Sep 2025	UK£271.9b	UK£87.6b	UK£11.7b	18.7x	23.2x	3.1x
Tue, 19 Aug 2025	UK£278.7b	UK£87.5b	UK£11.7b	21.7x	23.8x	3.2x
Thu, 17 Jul 2025	UK£258.5b	UK£86.7b	UK£10.7b	25.8x	24.3x	3x
Sat, 14 Jun 2025	UK£274.4b	UK£86.2b	UK£10.6b	27.2x	25.9x	3.2x
Mon, 12 May 2025	UK£258.4b	UK£87.2b	UK£10.7b	26.3x	24.2x	3x
Wed, 09 Apr 2025	UK£255.1b	UK£88.2b	UK£9.8b	29.2x	26x	2.9x
Fri, 07 Mar 2025	UK£291.4b	UK£87.9b	UK£9.6b	29.1x	30.3x	3.3x
Sun, 02 Feb 2025	UK£241.2b	UK£75.9b	UK£7.8b	33.6x	30.7x	3.2x
Tue, 31 Dec 2024	UK£223.1b	UK£75.5b	UK£7.8b	31.1x	28.6x	3x
Thu, 28 Nov 2024	UK£225.8b	UK£75.0b	UK£7.7b	31.9x	29.2x	3x
Sat, 26 Oct 2024	UK£247.0b	UK£72.5b	UK£9.1b	29.9x	27.2x	3.4x
Mon, 23 Sep 2024	UK£252.7b	UK£71.5b	UK£8.9b	37.8x	28.3x	3.5x
Wed, 21 Aug 2024	UK£275.9b	UK£72.3b	UK£9.0b	41.1x	30.6x	3.8x
Fri, 19 Jul 2024	UK£258.0b	UK£70.8b	UK£9.5b	35.5x	27.3x	3.6x
Sun, 16 Jun 2024	UK£267.2b	UK£71.6b	UK£9.6b	31.5x	27.9x	3.7x
Tue, 14 May 2024	UK£273.1b	UK£72.0b	UK£9.6b	37.2x	28.4x	3.8x
Thu, 11 Apr 2024	UK£242.0b	UK£71.1b	UK£9.7b	32.5x	24.8x	3.4x
Sat, 09 Mar 2024	UK£235.2b	UK£70.1b	UK£9.7b	31x	24.3x	3.4x
Mon, 05 Feb 2024	UK£237.0b	UK£69.8b	UK£9.5b	35.2x	24.8x	3.4x
Wed, 03 Jan 2024	UK£239.1b	UK£69.1b	UK£10.7b	35.8x	22.3x	3.5x
Fri, 01 Dec 2023	UK£226.1b	UK£69.1b	UK£10.7b	33.6x	21.1x	3.3x
Sun, 29 Oct 2023	UK£229.1b	UK£70.8b	UK£10.4b	54x	22.1x	3.2x
Tue, 26 Sep 2023	UK£250.4b	UK£70.6b	UK£10.4b	55.8x	24.2x	3.5x
Thu, 24 Aug 2023	UK£236.5b	UK£69.0b	UK£10.2b	53.5x	23.3x	3.4x
Sat, 22 Jul 2023	UK£237.3b	UK£67.4b	UK£7.8b	52x	30.3x	3.5x


GB Market	-0.95%
Healthcare	-9.75%
Pharma	-10.29%
Pharma	-10.29%

Company	Last Price	7D	1Y	Valuation
AGY Allergy Therapeutics	UK£0.074	12.1% +UK£50.7m	-7.5%	PS8.2x
HCM HUTCHMED (China)	UK£1.73	0.6% +UK£8.6m	-29.1%	PE4.4x
STX Shield Therapeutics	UK£0.063	2.5% +UK£1.6m	68.9%	PS1.8x
SAR Sareum Holdings	UK£0.23	4.5% +UK£1.4m	27.8%	PB26.7x
NFX Nuformix	UK£0.0017	3.0% +UK£130.5k	88.9%	PB2.7x

Announcement • Jul 01

Futura Medical Reports Highly Positive Data From WSD4000 Studies

Futura Medical reported the results from two studies on WSD4000: the Home User Test ('HUT') and the Placebo (Sham) Controlled Study. The positive results from both studies enhance the Company's belief in the commercial potential for WSD4000 and demonstrate that WSD4000 is superior to placebo (sham) thereby enabling it to proceed with the clinical study with high confidence of success. The Company expects to commence the clinical study by the end of 2026, subject to additional funding. WSD4000 was evaluated in 228 pre-, peri or post-menopausal women over a 4-week period. The results demonstrated that WSD4000 markedly improved sexual function from using the product. 78% of women reported a general improvement in all or most aspects of sex. 78% reported a more satisfying experience and 75% noticed having some increase in interest in having sex; 81% noticed an improvement to their overall sexual function. Overall, 68% of women rated the product 4 or 5 stars. 77% of participants had improved sexual experience after one use which increased to 84% after four uses. More specifically, after four uses: 83% of women experienced improved lubrication (wetness), 82% experienced improved genital sensation, 75% experienced improved arousal, 71% experienced faster arousal, 66% experienced greater ability to achieve orgasm, 61% experienced greater intensity of orgasm, 58% experienced less pain and discomfort during sex. The study also showed that, in general, the product was well tolerated, with only 18% of women experiencing a transient unpleasant sensory effect but many of those still wished to continue to use the product. The sensory effect described as unpleasant in some subjects can be mitigated when commercialised by clear consumer explanation highlighting that this is part of the mode of action of the product. The vast majority (84%) of women in the study claimed to like the sensory feel and lack of aroma of the product. A placebo ('sham' in US regulatory terminology) controlled study was conducted in order to design the most cost-effective clinical study to deliver a statistically significant and clinically meaningful result. WSD4000 was evaluated versus a placebo control in an "in-clinic" cross-over study in 33 pre- and post-menopausal women. WSD4000 was statistically superior to placebo in each of the key measures (arousal, genital sensation and lubrication) at 1 min, 2 min, 3 min, 5 min, 10 min and 15 min intervals. The results give the Company a high degree of confidence that WSD4000 will have superior efficacy to placebo (sham) in the pivotal clinical study and that subject numbers in the study will be at a cost-effective level. Independent research data conducted in the US with 1,000 subjects shows that 60% of women have suffered from at least one symptom of impaired sexual response and function in the prior twelve months. Only 1 in 4 of those impacted women seek professional help. Few women (13%) experience an improvement in symptoms over time and for 37% symptoms get worse over time. Currently, there is no known regulatory approved topical treatment globally for impaired sexual response and function in women that is available over the counter. Market research conducted by Ipsos showed 60% of women have experienced symptoms of sexual dysfunction over the last twelve months and 49% of women want to treat their symptoms. Current US female population between the ages of 22 and 75 is 113 million, of which 68 million experience symptoms. WSD4000 is a project name for our development female sexual health portfolio, starting with the creation of a range of topical gels under our unique platform technology, specifically designed to treat symptoms of sexual dysfunction in women. There is currently no known regulatory approved OTC treatment available for impaired sexual response and function in women. WSD4000 has the potential to be an effective, breakthrough treatment for the common symptoms associated with impaired sexual response and function, such as lack of desire, arousal, lubrication and ability to orgasm.

Announcement • Jun 12

Allergy Therapeutics plc Presents Data From Pollen And Food Allergy Research Portfolio And Hosts Symposium At EAACI Congress 2026

Allergy Therapeutics plc announced that it will be presenting data from across its pollen and food allergy research portfolio at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026, taking place in Istanbul, Türkiye, from 12 June 2026 through to 15 June 2026. Allergy Therapeutics will present 15 posters and oral presentations at the conference, including: Data from the Group's Phase I/IIa PROTECT trial of VLP Peanut, the Group's innovative, short-course peanut allergy immunotherapy candidate. The PROTECT trial met the primary endpoint, demonstrating a benign safety profile of VLP Peanut, with a strong dose-response in immunomodulating tolerogenic immune responses induced confirming clinical proof of concept. Blinded safety data from the first year of the Company's G308 Phase III trial evaluating the short- and long-term efficacy and safety of Grass MATA MPL in a paediatric population with grass-induced seasonal allergic rhinitis and rhinoconjunctivitis, demonstrating a benign safety profile in the first year of treatment and a low trial discontinuation rate. The Company will also host a symposium at the EAACI Congress from 15:00-16:00 TRT, co-chaired by Dr. Mohamed Shamji, Professor of Immunology and Allergy at Imperial College London, and Dr. Janice Layhadi, Research Associate at the Immunomodulation and Tolerance Group of Allergy & Clinical Immunology, Imperial College London. The symposium, titled Scoring Against Allergies: New Therapeutic Strategies on the Horizon, will focus on Allergy Therapeutics' ongoing work with Grass MATA MPL in a paediatric population and highlight the Company's progression of VLP Peanut as a novel therapeutic candidate for peanut allergy. In addition, the EAACI Early Career Research Award, supported by Allergy Therapeutics, will be presented to this year's recipient, Juan Luis Paris, PhD, at this year's congress. Juan Luis is a Principal Investigator at the Instituto de Investigación Biomédica de Málaga (IBIMA, Málaga, Spain), where his research is focused on developing bio- and nano-materials for therapeutic immunomodulation in allergic diseases and other pathologies. The EAACI Early Career Research Award provides an unrestricted research grant of up to EUR 30,000 and is open to EAACI Junior Members who have previously published their high-impact research on allergy and immunology and demonstrated their drive and dedication in the area of immunotherapy. Data from the Phase I/IIa PROTECT trial of VLP Peanut have confirmed a strong safety and tolerability profile of this novel immunotherapy candidate while also demonstrating clinical proof of concept, and preparations for the Group's Phase IIb trial are continuing. Clinical progress with Grass MATA MPL has continued following regulatory approval of the product in Germany, with encouraging paediatric safety data strengthening the evidence base that the product could provide a differentiated treatment option for grass-induced seasonal allergic rhinitis and rhinoconjunctivitis in a younger patient population. The complete list of Allergy Therapeutics-sponsored abstracts accepted by EAACI for presentation are available on the Group's website. No new material price sensitive information will be disclosed on Allergy Therapeutics at the EAACI Congress 2026.

U.K. (FTSE) Pharma Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Poolbeg Pharma PLC has completed a Follow-on Equity Offering in the amount of £3.5 million.

ECO Animal Health Group plc Provides Group Earnings Guidance for the Fiscal Year 2027

Jemperli Hits Key Mid-Stage Trial Goal in Advanced Rectal Cancer for GSK

Ionis Pharmaceuticals Provides Update on CARDIO-TTRansform Phase 3 Trial of Eplontersen in Adults with Transthyretin-Mediated Amyloid Cardiomyopathy

STX: Japan Trial Progress Will Drive Future Earnings Upside

HUTCHMED (China) Limited Receives NMPA Approval For ORPATHYS For Treatment Of Gastric Cancer Patients With MET Amplification

HLN: Lower Forward P E Assumptions Will Pressure Future Share Price

Futura Medical Reports Highly Positive Data From WSD4000 Studies

New minor risk - Financial data availability

Sareum Holdings PLC Publishes Phase 1 Clinical Data on SDC-1801 in British Journal Of Clinical Pharmacology

Hikma Pharmaceuticals PLC Welcomes FDA Approval of Guardant360 Liquid CDx

Allergy Therapeutics plc Presents Data From Pollen And Food Allergy Research Portfolio And Hosts Symposium At EAACI Congress 2026

New major risk - Shareholder dilution